Mirum Pharmaceuticals
MIRM
43 hedge funds and large institutions have $260M invested in Mirum Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 4 reducing their positions, and 5 closing their positions.
425% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 4
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
10% more funds holding
Funds holding: 39 → 43 (+4)
2.59% more ownership
Funds ownership: 70.68% → 73.27% (+2.6%)
35% less capital invested
Capital invested by funds: $398M → $260M (-$138M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$12.6M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.87M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$4.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.86M |
| 5 |
Axa
Paris,
France
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.75M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$217K |
| 3 |
LC
Lindbrook Capital
Calabasas,
California
|
-$49K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$46.8K |
| 5 |
Morgan Stanley
New York
|
-$46.1K |
MIRM Hedge Fund Activity: Q1 2020 in Review
43 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2020, worth a combined $260M — down 35% from $398M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MIRM positions and 5 closed out — a net gain of 4 holders — while 21 added to existing stakes and 4 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $12.6M. The largest seller was OrbiMed, exiting entirely with an estimated $1.75M sold.
- 43 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2020, up from 39 in Q4 2019.
- Funds reported $260M of Mirum Pharmaceuticals stock for Q1 2020, down 35% quarter-over-quarter.
- 9 funds opened new Mirum Pharmaceuticals positions in Q1 2020 and 5 closed out, a net change of +4 holders.
- The largest Mirum Pharmaceuticals buyer in Q1 2020 was Polar Capital, an estimated $12.6M added.
- The largest Mirum Pharmaceuticals seller in Q1 2020 was OrbiMed, an estimated $1.75M sold.
Based on aggregated 13F filings for Q1 2020.